によって Suwan Kim 2年前.
128
もっと見る
Combo BRAF/MEK inhibitor
Nivolumab + Ipilimumab
recommended first line for metastatic melanoma regardless of PDL1 expression
Pembrolizumab
Topical imiquimod or radiation if exclusion
Dabrafenib/trametinib (BRAF V600)
Ipilimumab
approved as single agent for resectable or metastatic melanoma
approved for adjuvant treatment after complete resection
approved for single agent and in combo w/ ipilmumab for unresectable or metastatic melanoma
Tox rash diarrhea liver tox hypophysitis
manage diarrhea and livertox w/ high dose steroids infliximab second line for diarrhea mycophendlate second line for liver tox
infliximab contraindicated in liver disease
has the highest tox among checkpoint inhibitors
also approved for adjuvant therapy for pt w/ mutation w/ lymph node involvement following complete resection